SEARCH

SEARCH BY CITATION

References

  • Armand, P., Kim, H.T., Ho, V.T., Cutler, C.S., Koreth, J., Antin, J.H., LaCasce, A.S., Jacobsen, E.D., Fisher, D.C., Brown, J.R., Canellos, G.P., Freedman, A.S., Soiffer, R.J. & Alyea, E.P. (2008) Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biology of Blood and Marrow Transplantation, 14, 418425.
  • Baron, F., Maris, M.B., Storer, B.E., Sandmaier, B.M., Stuart, M.J., McSweeney, P.A., Radich, J.P., Pulsipher, M.A., Agura, E.D., Chauncey, T.R., Maloney, D.G., Shizuru, J.A. & Storb, R. (2005) HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biology of Blood and Marrow Transplantation, 11, 272279.
  • Branson, K., Chopra, R., Kottaridis, P.D., McQuaker, G., Parker, A., Schey, S., Chakraverty, R.K., Craddock, C., Milligan, D.W., Pettengell, R., Marsh, J.C., Linch, D.C., Goldstone, A.H., Williams, C.D. & Mackinnon, S. (2002) Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. Journal of Clinical Oncology, 20, 40224031.
  • Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group (Review) [erratum appears in J Clin Oncol 2000 Jun;18(11):2351]. Journal of Clinical Oncology, 17, 1244.
  • Chopra, R., Goldstone, A.H., Pearce, R., Philip, T., Petersen, F., Appelbaum, F., De Vol, E. & Ernst, P. (1992) Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European bone marrow transplant group registry data. Journal of Clinical Oncology, 10, 16901695.
  • Dean, R.M., Fowler, D.H., Wilson, W.H., Odom, J., Steinberg, S.M., Chow, C., Kasten-Sportes, C., Gress, R.E. & Bishop, M.R. (2005) Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 11, 593599.
  • Dhedin, N., Giraudier, S., Gaulard, P., Esperou, H., Ifrah, N., Michallet, M., Milpied, N., Rio, B., Cahn, J.Y., Molina, L., Laporte, J.L., Guilhot, F. & Kuentz, M. (1999) Allogeneic bone marrow transplantation in aggressive non-Hodgkin’s lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. British Journal of Haematology, 107, 154161.
  • Doocey, R.T., Toze, C.L., Connors, J.M., Nevill, T.J., Gascoyne, R.D., Barnett, M.J., Forrest, D.L., Hogge, D.E., Lavoie, J.C., Nantel, S.H., Shepherd, J.D., Sutherland, H.J., Voss, N.J., Smith, C.A. & Song, K.W. (2005) Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. British Journal of Haematology, 131, 223230.
  • Escalon, M.P., Champlin, R.E., Saliba, R.M., Acholonu, S.A., Hosing, C., Fayad, L., Giralt, S., Ueno, N.T., Maadani, F., Pro, B., Donato, M., McLaughlin, P. & Khouri, I.F. (2004) Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin’s lymphoma whose disease has failed a prior autologous transplantation. Journal of Clinical Oncology, 22, 24192423.
  • Faulkner, R.D., Craddock, C., Byrne, J.L., Mahendra, P., Haynes, A.P., Prentice, H.G., Potter, M., Pagliuca, A., Ho, A., Devereux, S., McQuaker, G., Mufti, G., Yin, J.L. & Russell, N.H. (2004) BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 103, 428434.
  • Gribben, J.G., Goldstone, A.H., Linch, D.C., Taghipour, G., McMillan, A.K., Souhami, R.L., Earl, H. & Richards, J.D.M. (1989) Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin’s lymphomas who are still responsive to conventional-dose therapy. Journal of Clinical Oncology, 7, 16211629.
  • Haioun, C., Lepage, E., Gisselbrecht, C., Salles, G., Coiffier, B., Brice, P., Bosly, A., Morel, P., Nouvel, C., Tilly, H., Lederlin, P., Sebban, C., Briere, J., Gaulard, P. & Reyes, F. (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d’Etude des lymphomes de l’Adulte study. Journal of Clinical Oncology, 18, 30253030.
  • Law, L.Y., Horning, S.J., Wong, R.M., Johnston, L.J., Laport, G.G., Lowsky, R., Shizuru, J.A., Blume, K.G., Negrin, R.S. & Stockerl-Goldstein, K.E. (2006) High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 12, 703711.
  • De Lima, M., Van Besien, K.W., Giralt, S.A., Khouri, I.F., Mehra, R., Andersson, B.S., Przepiorka, D., Gajewski, J.L., Korbling, M. & Champlin, R.E. (1997) Bone marrow transplantation after failure of autologous transplant for non-Hodgkin’s lymphoma. Bone Marrow Transplantation, 19, 121127.
  • Maloney, D.G., Molina, A.J., Sahebi, F., Stockerl-Goldstein, K.E., Sandmaier, B.M., Bensinger, W., Storer, B., Hegenbart, U., Somlo, G., Chauncey, T., Bruno, B., Appelbaum, F.R., Blume, K.G., Forman, S.J., McSweeney, P. & Storb, R. (2003) Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 102, 34473454.
  • Maris, M.B., Niederwieser, D., Sandmaier, B.M., Storer, B., Stuart, M., Maloney, D., Petersdorf, E., McSweeney, P., Pulsipher, M., Woolfrey, A., Chauncey, T., Agura, E., Heimfeld, S., Slattery, J., Hegenbart, U., Anasetti, C., Blume, K. & Storb, R. (2003) HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood, 102, 20212030.
  • Mills, W., Chopra, R., McMillan, A., Pearce, R., Linch, D.C. & Goldstone, A.H. (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 13, 588595.
  • Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G.M., Parker, A., Schey, S., Chopra, R., Hatton, C., Tighe, J., Hunter, A., Peggs, K., Linch, D., Goldstone, A. & Mackinnon, S. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104, 38653871.
  • Peniket, A.J., Ruiz, D.E.M., Taghipour, G., Cordonnier, C., Gluckman, E., De Witte, T., Santini, G., Blaise, D., Greinix, H., Ferrant, A., Cornelissen, J., Schmitz, N. & Goldstone, A.H. (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplantation, 31, 667678.
  • Petersdorf, E.W., Gooley, T.A., Anasetti, C., Martin, P.J., Smith, A.G., Mickelson, E.M., Woolfrey, A.E. & Hansen, J.A. (1998) Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood, 92, 35153520.
  • Petersen, F.B., Appelbaum, F.R., Hill, R., Fisher, L.D., Bigelow, C.L., Sanders, J.E., Sullivan, K.M., Bensinger, W.I., Witherspoon, R.P., Storb, R., Clift, R.A., Fefer, A., Press, O.W., Weiden, P.L., Singer, J., Thomas, E.D. & Buckner, C.D. (1990) Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. Journal of Clinical Oncology, 8, 638647.
  • Philip, T., Armitage, J.O., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J.-Y., Colombat, P., Goldstone, A.H., Gorin, N.C., Flesh, M., Laporte, J.-P., Maraninchi, D., Pico, J., Bosly, A., Anderson, C., Schots, R., Biron, P., Cabanillas, F. & Dicke, K. (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. New England Journal of Medicine, 316, 14931498.
  • Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht Cahn, J.-Y., Harousseau, J.-L., Coiffier, B., Biron, P., Mandell, F. & Chauvin, F. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New England Journal of Medicine, 333, 15401545.
  • Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.-G., Beatty, P., Hows, J. & Thomas, E.D. (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplantation, 15, 825828.
  • Radich, J.P., Gooley, T., Sanders, J.E., Anasetti, C., Chauncey, T. & Appelbaum, F.R. (2000) Second allogeneic transplantation after failure of first autologous transplantation. Biology of Blood and Marrow Transplantation, 6, 272279.
  • Ratanatharathorn, V., Uberti, J., Karanes, C., Abella, E., Lum, L.G., Momin, F., Cummings, G. & Sensenbrenner, L.L. (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma. Blood, 84, 10501055.
  • Rezvani, A.R., Storer, B., Maris, M., Sorror, M.L., Agura, E., Maziarz, R.T., Wade, J.C., Chauncey, T., Forman, S.J., Lange, T., Shizuru, J., Langston, A., Pulsipher, M.A., Sandmaier, B.M., Storb, R. & Maloney, D.G. (2008) Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin lymphoma. Journal of Clinical Oncology, 28, 211217.
  • Robinson, S.P., Goldstone, A.H., Mackinnon, S., Carella, A., Russell, N., De Elvira, C.R., Taghipour, G. & Schmitz, N. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood, 100, 43104316.
  • Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. & Storer, B. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 29122919.
  • Sullivan, K.M., Agura, E., Anasetti, C., Appelbaum, F.R., Badger, C., Bearman, S., Erickson, K., Flowers, M., Hansen, J.A., Loughran, T., Martin, P., Matthews, D., Petersdorf, E., Radich, J., Riddell, S., Rovira, D., Sanders, J., Schuening, F., Siadak, M., Storb, R. & Witherspoon, R.P. (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Seminars in Hematology, 28, 250259.
  • The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. New England Journal of Medicine, 329, 987994.
  • The Non-Hodgkin’s Lymphoma Classification Project. (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood, 89, 39093918.
  • Tsai, T., Goodman, S., Saez, R., Schiller, G., Adkins, D., Callander, N., Wolff, S. & Freytes, C.O. (1997) Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplantation, 20, 859863.
  • Vose, J.M., Bierman, P.J., Anderson, J.R., Kessinger, A., Pierson, J., Nelson, J., Frappier, B., Schmit-Pokorny, K., Weisenburger, D.D. & Armitage, J.O. (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood, 80, 21422148.